Abstract
There is a surge of new interest in C. difficile infection (CDI) reflecting substantial increases in cases and fatalities. The new challenges by this now old pathogen have brought renewed interest in all facets of the disease. Particularly important are the role of fluoroquinolones as inducing agents, the new polymerase chain reaction test to detect toxigenic strains in stools, the important role of the NAP-1 strain, recent evidence favoring oral vancomycin over metronidazole in seriously ill patients, and new guidelines for management.
Original language | English (US) |
---|---|
Pages (from-to) | 62-69 |
Number of pages | 8 |
Journal | Annals of the New York Academy of Sciences |
Volume | 1213 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2010 |
Keywords
- Antibiotic-associated colitis
- C. difficile
- Clostridium difficile
- Epidemiology
- Fluoroquinolones
- New guidelines, tests, and treatments
- Oral vancomycin
- Pseudomenbraneous colitis
ASJC Scopus subject areas
- Neuroscience(all)
- Biochemistry, Genetics and Molecular Biology(all)
- History and Philosophy of Science